Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/21548331.1992.11705372 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Leishmaniasis in deployed military populations: A systematic review and meta-analysis.
PLoS Negl Trop Dis
March 2025
School of Life Sciences, University of Warwick, Warwick, United Kingdom.
Leishmaniasis affects military personnel deployed to endemic areas following exposure to sand flies infected with the protozoa Leishmania. This systematic review and meta-analysis of data specific to military populations aims to identify knowledge gaps to mitigate sand fly exposure and Leishmania transmission during deployments. The review was registered on PROSPERO (CRD42023463687).
View Article and Find Full Text PDFKala-azar elimination in India: reflections on success and sustainability.
Int Health
March 2025
Directorate of National Centre for Disease Control, New Delhi 110054, India.
The incidence and mortality of kala-azar (KA, visceral leishmaniasis) in India have fallen drastically in the past few years, and in 2023 the reported KA incidence reached the threshold for elimination as a public health problem (<1 case/10 000 of population at subdistrict level). One of the strategies adopted by India's kala-azar elimination program (KAEP) was the regular independent assessment of the program implementation by teams of experts. We present the findings of assessments undertaken in 2019, 2021 and 2023, when the KAEP was in the last mile of elimination.
View Article and Find Full Text PDFPatient insights research exploring disease awareness, patient life experience, and current management of visceral leishmaniasis in Bihar, India.
PLoS Negl Trop Dis
February 2025
Novartis Pharma A.G., Basel, Switzerland.
Background: Visceral leishmaniasis (VL) is a vector-borne disease caused by Leishmania parasites and transmitted by sand fly bites, targeted for elimination in India. VL primarily affects rural, low-income populations with limited health care access. In South Asia, few studies have explored patients' perspectives, diagnoses, and treatment experiences; particularly lacking an understanding about the patients' life experiences outside of clinical research settings.
View Article and Find Full Text PDFTargeted Oral Fixed-Dose Combination of Amphotericin B-Miltefosine for Visceral Leishmaniasis.
Mol Pharm
March 2025
Departamento de Farmacia Galénica y Tecnología Alimentaria, Facultad de Farmacia, Universidad Complutense de Madrid. Plaza de Ramón y Cajal, s/n, 28040 Madrid, Spain.
The incidence of visceral leishmaniasis (VL) remains a significant health threat in endemic countries. Fixed-dose combination (FDC) of amphotericin B (AmB) and miltefosine (MLT) is a promising strategy for treating VL, but the parenteral administration of AmB leads to severe side effects, limiting its use in clinical practice. Here, we developed novel FDC granules combining AmB in the core with a MLT coating using wet granulation followed by the fluidized bed technology.
View Article and Find Full Text PDFLmCen based vaccine is protective against canine visceral leishmaniasis following three natural exposures in Tunisia.
NPJ Vaccines
February 2025
Laboratory of Transmission, Control, and Immunobiology of Infections. Pasteur Institute of Tunis. University of Tunis El Manar, Tunis, Tunisia.
Dogs are the main reservoir host of Leishmania infantum, etiological agent of zoonotic visceral leishmaniasis (ZVL). An effective vaccine against Canine Visceral Leishmaniasis (CVL) will help the control and elimination of ZVL. In this study, we evaluated in dogs the safety, immunogenicity, and efficacy of a live attenuated Leishmania major Centrin gene-deleted (LmCen) as a vaccine.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!